Latest Us Expansion News

IODM has secured the first 15 university commitments in its planned 283-university US rollout, while revenue rose 10.2% despite a sharp fall in UK international student visa applications. The onboarding is not yet revenue, but the December-quarter target gives investors a clear execution test.

Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.

Metallium has completed a 12-hour campaign using three Flash Joule Heating reactors to process platinum-group-metal-bearing catalytic converter material under reactive chlorination conditions. The milestone advances the company’s scale-up program, but recovery results, product economics and feedstock grades remain unverified.

Peak Processing delivered its first positive Group EBITDA quarter in FY2026, but the turnaround remains financially fragile. The ASX-listed THC beverage manufacturer reported a $7.8 million statutory loss, negative operating cash flow and an explicit material uncertainty over its ability to continue as a going concern.

SQX Resources Limited (ASX:SQX) has emerged from a transformational year with two advanced US gold projects, broad shallow mineralisation at Red Bird and exceptional underground assays at Williams. The exploration gains came alongside a $1.83 million loss, falling cash and a further $2.47 million capital raising completed after year-end.

Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.

RMA Global has replaced its chief executive and moved to a new chair as it targets a simpler, faster and more profitable business across Australia, New Zealand and the United States. The company has set an EBITDA improvement objective for FY27, but has not yet quantified the plan.

Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Infratil has raised FY27 earnings guidance as data-centre demand accelerates across CDC and Longroad, with AI infrastructure now representing 73% of its NZ$22 billion asset base. The company is also sharpening its strategy around scaled growth platforms, contracted cash flows and selective new investments.